Differences in the Personality Profile of Medication-Overuse Headache Sufferers and Drug Addict Patients: A Comparative Study Using MMPI-2

Galli, Federica; Pozzi, Gino; Frustaci, Alessandra; Allena, Marta; Anastasi, Serena; Chirumbolo, Antonio; Ghiotto, Natascia; Guidetti, Vincenzo; Matarrese, Adriana; Nappi, Giuseppe; Pazzi, Stefania; Quartesan, Roberto; Sances, Grazia; Tassorelli, Cristina

doi:10.1111/j.1526-4610.2011.01978.x

Cited by 31 publications

(38 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study was designed in agreement with the recent EFNS guidelines for the treatment of MOH (Evers and Jensen, 2011). Our study confirms previous observations about the occurrence of psychopathological disturbances in chronic headache patients with MOH (Radat et al, 2005;Atasoy et al, 2005;Sances et al, 2010;Galli et al, 2011). However, we did not find that VPA had a significant effect on psychopathological comorbidity, suggesting that its anti-migraine action is independent from its potential impact on the underlying psychopathology.…”

Section: Vpa Nsupporting

confidence: 79%

Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial

Sarchielli

Messina

Cupini

et al. 2014

European Neuropsychopharmacology

View full text Add to dashboard Cite

Objective: To assess the efficacy, safety and tolerability of sodium valproate (800 mg/die) compared with placebo in medication-overuse headache patients with a history of migraine without aura.Methods: This is a multicenter, randomized, double-blind, placebo-controlled study enrolled medication-overuse headache patients for a 3-month treatment period with sodium valproate (800 mg/day) or placebo after a 6 day outpatient detoxification regimen, followed by a 3-month follow-up. Primary outcome was defined by the proportion of patients achieving Z50% reduction in the number of days with headache per month (responders) from the baseline to the last 4 weeks of the 3-month treatment. Multivariate logistic regression models were used on the primary endpoint, adjusting for age, sex, disease duration, comorbidity and surgery. The last-observation-carried-forward method was used to adjust for missing values.Results: Nine sites enrolled 130 patients and, after a 6-day detoxification phase, randomized 88 eligible patients. The 3-month responder rate was higher in the sodium valproate (45.0%) than in the placebo arm (23.8%) with an absolute difference of about 20% (p=0.0431). Sodium valproate had safety and tolerability profiles comparable to placebo. Conclusions:The present study supports the efficacy and safety of sodium valproate in the treatment of medication overuse headache with history of migraine after detoxification.

show abstract

Section: Vpa Nsupporting

confidence: 79%

Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial

Sarchielli

Messina

Cupini

et al. 2014

European Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

“…patientsNo. medication overuse headacheAnalgesicsErgotsOpioidsTriptansAltieri et al 2009 [11]ItalyICHD-2 [7]Clinic2711NRNR4Ayzenberg et al 2008 [12]GermanyICHD-2 [7]Clinic2914NRNR15Biagianti et al 2012 [13]ItalyICHD-2 Revised [8]Clinic5226NRNR20Boe et al 2007 [14]NorwayICHD-2 Appendix [7]Clinic100201NR23Coppola et al 2010 [15]ItalyICHD-2 Appendix [7]Clinic2910NRNR9Cupini et al 2009 [16]ItalyICHD-2 Appendix [7]Clinic33NR1NR4Di Lorenzo et al 2009 [17]ItalyICHD-2 [7]Clinic10718NRNR29Donnet et al 2009 [18]FranceICHD-2 [7]Population320157252964Dousset et al 2013 [19]FranceICHD-2 Appendix [7]Clinic428109Galli et al 2011 [20]ItalyICHD-2Appendix [7]Clinic82212322Gambini et al 2013 [21]ItalyICHD-2 Revised [8]Clinic6333NRNR21…”

Section: Methodsmentioning

confidence: 99%

Risk of medication overuse headache across classes of treatments for acute migraine

et al. 2016

View full text Add to dashboard Cite

BackgroundThe most commonly prescribed medications used to treat migraine acutely are single analgesics, ergots, opioids, and triptans. Due to varying mechanisms of action across drug classes, there is reason to believe that some classes may be less likely than others to elicit Medication Overuse Headache (MOH) than others. We therefore aimed to determine whether certain classes of acute migraine drugs are more likely to elicit MOH than others.MethodsA comprehensive systematic literature was conducted to identify studies of varying designs that reported on MOH within the considered treatment classes. Only studies that reported MOH according to the International Classification of Headache Disorders (ICHD) were considered. Since no causal comparative design studies were identified; data from prevalence studies and surveys were retrieved. Prevalence-based relative risks between treatment classes were calculated by integrating both medication overuse and medication use from published studies. For each pair wise comparison, pooled relative risks were calculated as the inverse variance weighted average.ResultsA total of 29 studies informed the relative risk between treatment classes, all of which reported country-specific data. Five studies reported country-specific medication use data. For triptans versus analgesics the study relative risks generally favored triptans. The pooled relative risk was 0.65 (i.e., relative risk reduction of 35 %). For ergots versus analgesics, a similar trend was observed in favor of ergots with a relative risk of 0.41. For triptans versus ergots, the direction of effect was mixed, and the pooled relative risk was 1.07. Both triptans and ergots appeared favorable when compared to opioids, with pooled relative risks of 0.35 and 0.76, respectively. However, the evidence was limited for these comparisons. Analgesics and opioids also appeared to yield similar risk of MOH (pooled relative risk 1.09).ConclusionOur study suggests that in patients receiving acute migraine treatment, analgesics and opioids are associated with a higher risk of developing MOH compared with other treatments. These findings provide incentive for better monitoring of use of analgesics and opioids for treating acute migraine, and suggest possible clinical preference for use of so-called “migraine-specific” treatments, that is, triptans and ergots.Electronic supplementary materialThe online version of this article (doi:10.1186/s10194-016-0696-8) contains supplementary material, which is available to authorized users.

show abstract

“…However, use of DSM-IV criteria in patients with MOH has been criticized since it may overestimate dependence 125. In other studies, the dependence and personality profile score in the Minnesota Multiphasic Personality Inventory II (MMPI-II) did not reveal any differences between MOH patients, drug addicts, and controls 126,127…”

Section: Medication Dependence In Moh?mentioning

confidence: 98%

Medication-overuse headache: a review

Kristoffersen

Lundqvist²

2014

JPR

View full text Add to dashboard Cite

Medication-overuse headache (MOH) is a worldwide health problem with a prevalence of 1%–2%. It is a severe form of headache where the patients often have a long history of headache and of unsuccessful treatments. MOH is characterized by chronic headache and overuse of different headache medications. Through the years, withdrawal of the overused medication has been recognized as the treatment of choice. However, currently, there is no clear consensus regarding the optimal strategy for management of MOH. Treatment approaches are based on expert opinion rather than scientific evidence. This review focuses on aspects of epidemiology, diagnosis, pathogenesis, prevention, and treatment of MOH. We suggest that information and education about the risk of MOH is important since the condition is preventable. Most patients experience reduction of headache days and intensity after successful treatment. The first step in the treatment of MOH should be carried out in primary care and focus primarily on withdrawal, leaving prophylactic medication to those who do not manage primary detoxification. For most patients, a general practitioner can perform the follow-up after detoxification. More complicated cases should be referred to neurologists and headache clinics. Patients suffering with MOH have much to gain by an earlier treatment-focused approach, since the condition is both preventable and treatable.

show abstract

Differences in the Personality Profile of Medication-Overuse Headache Sufferers and Drug Addict Patients: A Comparative Study Using MMPI-2

Cited by 31 publications

References 50 publications

Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial

Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial

Risk of medication overuse headache across classes of treatments for acute migraine

Medication-overuse headache: a review

Contact Info

Product

Resources

About